AtaiBeckley (ATAI) Share-based Compensation (2020 - 2026)
AtaiBeckley (ATAI) recorded quarterly Share-based Compensation of $5.4 million in Q1 2026, up 62.38% quarter-over-quarter from $3.4 million in Q1 2025, and up 62.38% on a YoY basis from $3.4 million in Q1 2025.
AtaiBeckley (ATAI) Share-based Compensation (2020 - 2026) Analysis & Trends
AtaiBeckley has disclosed Share-based Compensation across 6 years of filings, most recently posting $9000.0 for Q2 2025.
- Share-based Compensation for Q2 2025 came in at $9000.0, down 99.61% year-over-year; the trailing twelve-month figure through Sep 2025 was $11.8 million (down 23.62% YoY), and the FY2024 annual result was $25.5 million, down 22.72% from the prior year.
- Share-based Compensation was $5.4 million for Q1 2026 at AtaiBeckley, up from $3.4 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $5.4 million in Q1 2026 to a low of $3.4 million in Q1 2025.
- The 5-year median for Share-based Compensation is $6.9 million (2023), against an average of $6.5 million.
- Across the five-year window, Share-based Compensation jumped 4715.09% in 2022 and slumped 99.78% in 2024, its largest moves.
- AtaiBeckley's Share-based Compensation stood at $13.4 million in 2021, then slipped by 9.39% to $12.1 million in 2022, then plunged by 39.83% to $7.3 million in 2023, then grew by 15.02% to $8.4 million in 2024, then slumped by 99.89% to $9000.0 in 2025.
- The last three Share-based Compensation figures came in at $9000.0 (Q2 2025), $3.4 million (Q1 2025), and $8.4 million (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 305,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 166.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 26.47 Mn |
| 10 | AtaiBeckley | 1.45 Bn | 1.45 Bn | - | 5.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.45 Mn |
| Mar 31, 2026 | 5.45 Mn |
| Jun 30, 2025 | 9,000.00 |
| Jun 30, 2025 | 9,000.00 |
| Mar 31, 2025 | 3.36 Mn |
| Mar 31, 2025 | 3.36 Mn |
| Mar 31, 2025 | 3.36 Mn |
| Mar 31, 2025 | 3.36 Mn |
| Dec 31, 2024 | 8.40 Mn |
| Dec 31, 2024 | 8.40 Mn |
| Sep 30, 2024 | 15,000.00 |
| Sep 30, 2024 | 15,000.00 |
| Jun 30, 2024 | 2.33 Mn |
| Jun 30, 2024 | 2.33 Mn |
| Mar 31, 2024 | 5.76 Mn |
| Mar 31, 2024 | 5.76 Mn |
| Dec 31, 2023 | 7.31 Mn |
| Dec 31, 2023 | 7.31 Mn |
| Sep 30, 2023 | 6.90 Mn |
| Sep 30, 2023 | 6.90 Mn |